{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:41:30Z","timestamp":1740120090996,"version":"3.37.3"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002461","name":"Chungbuk National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002461","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clinthera.2024.06.013","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T03:16:06Z","timestamp":1721445366000},"page":"622-628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacodynamics Between a Dual Delayed-Release Formulation of Low-Dose Esomeprazole and Famotidine in Healthy Korean Subjects"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2476-2408","authenticated-orcid":false,"given":"Young-Sim","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Gi","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyojin","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Hwan","family":"Seong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Hee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-7555","authenticated-orcid":false,"given":"Min Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.06.013_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246619","article-title":"Prevalence and associated risk factors of gastritis among patients visiting Saint Paul Hospital millennium medical college, Addis Ababa, Ethiopia","volume":"16","author":"Feyisa","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0002","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2165\/00003088-199120030-00004","article-title":"Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations","volume":"20","author":"Lin","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4166\/kjg.2017.70.1.4","article-title":"The effect of H(2) receptor antagonist in acid inhibition and its clinical efficacy","volume":"70","author":"Shim","year":"2017","journal-title":"Korean J Gastroenterol"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0004","series-title":"StatPearls","article-title":"H2 blockers","author":"Nugent","year":"2023"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0005","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.dld.2017.03.019","article-title":"Sex-differences in the prevalence of helicobacter pylori infection in pediatric and adult populations: systematic review and meta-analysis of 244 studies","volume":"49","author":"Ibrahim","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0006","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors","volume":"10","author":"Shin","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0007","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000381419","article-title":"Potent gastric acid inhibition over 24 hours by 4-times daily dosing of esomeprazole 20 mg","volume":"91","author":"Sahara","year":"2015","journal-title":"Digestion"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0008","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5056\/jnm18001","article-title":"Advantages and disadvantages of long-term proton pump inhibitor use","volume":"24","author":"Kinoshita","year":"2018","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0009","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.3390\/ijerph18073527","article-title":"Effect of food and dosing regimen on safety and efficacy of proton pump inhibitors therapy-a literature review","volume":"18","author":"Wiesner","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and pharmacodynamics of the proton pump inhibitors","volume":"19","author":"Shin","year":"2013","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0012","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5056\/jnm18001","article-title":"Advantages and disadvantages of long-term proton pump inhibitor use","volume":"24","author":"Kinoshita","year":"2018","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0013","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.3390\/ijerph18073527","article-title":"Effect of food and dosing regimen on safety and efficacy of proton pump inhibitors therapy\u2014a literature review","volume":"18","author":"Wiesner","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0014","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/cpdd.1237","article-title":"Effect of food on the pharmacokinetics and pharmacodynamics of a novel dual delayed-release formulation of esomeprazole in healthy subjects","volume":"12","author":"Hwang","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0015","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2147\/DDDT.S392533","article-title":"Pharmacokinetics and pharmacodynamics of Esomezol DR, a new dual delayed-release formulation of esomeprazole 20 mg or 40 mg, in healthy subjects","volume":"17","author":"Kim","year":"2023","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.clinthera.2024.06.013_bib0016","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/apt.14818","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects","volume":"48","author":"Sunwoo","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2024.06.013_bib0017","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2036.2005.02468.x","article-title":"Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease","volume":"21","author":"Fujiwara","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0018","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.3346\/jkms.2023.38.e115","article-title":"Clinical practice guideline for gastritis in Korea","volume":"38","author":"Kim","year":"2023","journal-title":"J Korean Med Sci"},{"issue":"9","key":"10.1016\/j.clinthera.2024.06.013_bib0019","doi-asserted-by":"crossref","first-page":"377","DOI":"10.5414\/CP204391","article-title":"Comparison of the acid suppression effects between low-dose esomeprazole and famotidine in healthy subjects","volume":"61","author":"Kim","year":"2023","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5009\/gnl220446","article-title":"Evaluation of the efficacy and safety of DW1903 in patients with gastritis: a randomized, double-blind, noninferiority, multicenter, phase 3 study","volume":"18","author":"Kim","year":"2024","journal-title":"Gut Liver"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0021","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1440-1746.2003.03041.x","article-title":"Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection","volume":"18","author":"Komazawa","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0022","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2036.2001.00980.x","article-title":"Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes","volume":"15","author":"Horai","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2024.06.013_bib0023","first-page":"11","article-title":"Nocturnal acid breakthrough\u2014approach to management","volume":"6","author":"Tutuian","year":"2004","journal-title":"MedGenMed"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2024.06.013_bib0024","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.02943.x","article-title":"Review article: the clinical pharmacology of proton pump inhibitors","volume":"23","author":"Sachs","year":"2006","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824001516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824001516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T16:30:18Z","timestamp":1724949018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824001516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0149291824001516"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamics Between a Dual Delayed-Release Formulation of Low-Dose Esomeprazole and Famotidine in Healthy Korean Subjects","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}